Alnylam Pharmaceuticals | ALNY - Debt


Alnylam Pharmaceuticals reported $1.27B in Debt for its fiscal quarter ending in March of 2026.





Debt Change Date
Acadia Pharmaceuticals USD 50.79M 1.39M Mar/2026
Agios Pharmaceuticals USD 35.74M 4.46M Mar/2026
Alnylam Pharmaceuticals USD 1.27B 5.33M Mar/2026
Amgen USD 57.32B 2.72B Mar/2026
Arrowhead Research USD 983.69M 5.77M Jun/2026
BioCryst Pharmaceuticals USD 828.6M 510K Dec/2024
BioMarin Pharmaceutical USD 1.44B 833.74M Mar/2026
Incyte USD 38.27M 1.16M Jun/2026
Ionis Pharmaceuticals USD 1.91B 425.5M Jun/2026
Moderna USD 1.3B 7M Mar/2026
Neurocrine Biosciences USD 406.2M 9.1M Mar/2026
Novartis USD 47B 14.98B Mar/2026
PTC Therapeutics USD 286.94M 2.42B Mar/2026
Regeneron Pharmaceuticals USD 2.71B 400K Jun/2026
Sangamo BioSciences USD 0 0 Jun/2022
Sanofi EUR 20.02B 1.73B Mar/2026
Sarepta Therapeutics USD 1.04B 3.08M Mar/2026
Takeda JPY 4.94T 58.13B Jun/2026
Tectonic Therapeutic USD 876K 115K Dec/2024
Ultragenyx Pharmaceutical USD 36M 2.17M Dec/2025
Vertex Pharmaceuticals USD 1.98B 8.9M Jun/2026
Xencor USD 175.16M 12.58M Mar/2026